Open AccessIncreased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe
Author(s) -
C Thorne,
Darshak Patel,
Marie-Louìse Newell
Publication year - 2004
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200411190-00019
Subject(s) - medicine , pregnancy , antiretroviral therapy , gestation , obstetrics , adverse effect , pediatrics , human immunodeficiency virus (hiv) , viral load , immunology , biology , genetics
Highly active antiretroviral therapy (HAART) may be associated with adverse pregnancy outcomes. Among 4372 live births in the European Collaborative Study, the prematurity rate increased to 24.9% in 2000-2004. Antenatal HAART use initiated pre-pregnancy was strongly associated with prematurity (AOR 2.05, 95% CI 1.43, 2.95), particularly severe prematurity. The implication of increased prematurity is evidenced in high neonatal mortality in these groups (0.66% for infants at 34-36 weeks and 7.37% at < 34 weeks' gestation).